NasdaqGM:CRSPBiotechs
Why CRISPR Therapeutics (CRSP) Is Up 6.1% After Positive CTX310 Trial and Earnings Beat
Earlier this week, CRISPR Therapeutics reported quarterly results that surpassed expectations, driven by reduced R&D spending and encouraging clinical progress, including positive Phase 1 data for CTX310 and advancements in SyNTase gene editing technology.
This momentum, coupled with upward revisions in earnings estimates despite ongoing losses, has sparked heightened investor interest and renewed analyst confidence in the company's pipeline developments.
We'll explore how CTX310's Phase 1...